These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9127745)

  • 21. Simultaneous high-performance liquid chromatographic analysis of carbidopa, levodopa and 3-O-methyldopa in plasma and carbidopa, levodopa and dopamine in urine using electrochemical detection.
    Titus DC; August TF; Yeh KC; Eisenhandler R; Bayne WF; Musson DG
    J Chromatogr; 1990 Dec; 534():87-100. PubMed ID: 2094725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
    Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
    Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection.
    Holmes C; Eisenhofer G; Goldstein DS
    J Chromatogr B Biomed Appl; 1994 Mar; 653(2):131-8. PubMed ID: 8205240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A method for very rapid determinations of catechols using ion-pairing reverse phase HPLC with electrochemical detection: effects of L-dopa treatment on the catechol content in various rat brain structures.
    Ehrenström F; Johansson P
    Life Sci; 1985 Mar; 36(9):867-79. PubMed ID: 3974414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-dopa facilitates the release of endogenous norepinephrine and dopamine via presynaptic beta 1- and beta 2-adrenoceptors under essentially complete inhibition of L-aromatic amino acid decarboxylase in rat hypothalamic slices.
    Goshima Y; Nakamura S; Misu Y
    Jpn J Pharmacol; 1990 May; 53(1):47-56. PubMed ID: 1972204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W; Naoi M; Narabayashi H
    J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of levodopa and biogenic amines in urine samples using high-performance liquid chromatography.
    Baranowska I; Płonka J
    J Chromatogr Sci; 2008 Jan; 46(1):30-4. PubMed ID: 18218185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
    Nakazato T; Akiyama A
    Brain Res; 2002 Mar; 930(1-2):134-42. PubMed ID: 11879803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of cysteinyldopas, dopa, dopamine, noradrenaline and adrenaline in serum and urine using high-performance liquid chromatography and electrochemical detection.
    Hansson C; Agrup G; Rorsman H; Rosengren AM; Rosengren E; Edholm LE
    J Chromatogr; 1979 Jan; 162(1):7-22. PubMed ID: 33194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease.
    van der Geest R; Kruger P; Gubbens-Stibbe JM; van Laar T; Bodde HE; Danhof M
    J Chromatogr B Biomed Sci Appl; 1997 Nov; 702(1-2):131-41. PubMed ID: 9449564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of levodopa, dopamine and its metabolites in rat striatum dialysates following peripheral administration of L-DOPA prodrugs by mean of HPLC-EC.
    Cannazza G; Di Stefano A; Mosciatti B; Braghiroli D; Baraldi M; Pinnen F; Sozio P; Benatti C; Parenti C
    J Pharm Biomed Anal; 2005 Jan; 36(5):1079-84. PubMed ID: 15620535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
    Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
    Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson's disease patients.
    Rajda C; Dibó G; Vécsei L; Bergquist J
    Neuroimmunomodulation; 2005; 12(2):81-4. PubMed ID: 15785109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of Parkinsonian patients.
    Bronaugh RL; Hattox SE; Hoehn MM; Murphy RC; Rutledge CO
    J Pharmacol Exp Ther; 1975 Dec; 195(3):441-52. PubMed ID: 1195131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart failure, aging, and renal synthesis of dopamine.
    Ferreira A; Bettencourt P; Pestana M; Correia F; Serrão P; Martins L; Cerqueira-Gomes M; Soares-Da-Silva P
    Am J Kidney Dis; 2001 Sep; 38(3):502-9. PubMed ID: 11532681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-dopa therapy for Parkinson's disease: past, present, and future.
    Nagatsua T; Sawadab M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.